BRIEF—Takeda given UK reimbursement for Adcetris

Takeda has been awarded a positive reimbursement decision in the UK regarding Adcetris (brentuximab vedotin) as a second-line therapy for certain people with advanced cutaneous T-cell lymphoma (CTCL).

CTCL is a rare and normally incurable form of non-Hodgkin lymphoma. The decision from the National Institute for Health and Care Excellence (NICE) means the drug can be used routinely by the country’s national healthcare provider.

Takeda’s UK managing director Jon Neal said: “We are really pleased NICE has approved brentuximab vedotin for patients with the most debilitating forms of CTCL.”